Progenics Pharmaceuticals (PGNX) has risen sharply, recording gains of 11.97% in the past 4 weeks. However, the stock has corrected -3.96% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 12.2% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
For this week, the average consensus of the company shares are rated as a Strong Buy. The stock has recorded a twenty day Moving Average of 0.98% and the fifty day Moving Average is 16.13%. Progenics Pharmaceuticals, Inc. is up 33.95% in the last three month period. Year-to-Date the stock performance stands at 6.85%.
Progenics Pharmaceuticals (PGNX) : Average target price received by Progenics Pharmaceuticals (PGNX) is $11.5 with an expected standard deviation of $3.54. The most aggressive target on the stock is $14, whereas the most downbeat target is $9. 2 financial analysts are currently covering the stock.
Progenics Pharmaceuticals (NASDAQ:PGNX): stock turned positive on Friday. Though the stock opened at $6.54, the bulls momentum made the stock top out at $6.72 level for the day. The stock recorded a low of $6.41 and closed the trading day at $6.55, in the green by 0.46%. The total traded volume for the day was 1,131,297. The stock had closed at $6.52 in the previous days trading.
Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).